Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIND-014 in metastatic castration-resistant prostate cancer
NCT01812746Phase 2Completed
- Sponsor
- BIND Therapeutics
- Start
- Apr 2013
- Primary completion
- Apr 2016
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of BIND-014 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by BIND Therapeutics. Started Apr 2013; status: completed.
02
Drugs
BIND-014
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01812746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812746.